HAGA.BIO announced the successful closing of a $2.3 million seed financing round as the company advances commercialization of its spatial biology technologies and expands development of its RNA detection platform.
The funding marks an important milestone for the company as it seeks to bring its products to market and further develop technologies focused on in situ RNA detection at single nucleotide resolution.
According to the company, its platform is designed to help bridge the gap between scientific discovery and clinical translation by enabling highly precise RNA biomarker analysis at the molecular level.
HAGA.BIO’s technology focuses on detecting RNA signatures with single nucleotide resolution, supporting applications involving RNA biomarkers, single nucleotide variants (SNVs), and mutation analysis, including KRAS-related research.
The company said the new capital will support both commercialization efforts and continued technology development as it works with researchers, partners, and early adopters in the spatial biology and precision medicine markets.
HAGA.BIO also expressed appreciation to its investors, team members, partners, and customers who have supported the company’s growth and technology development efforts.
